PubRank

David A Flockhart

Author PubWeight™ 167.48‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003 8.66
2 Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005 6.90
3 CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005 5.92
4 Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008 5.38
5 Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006 4.81
6 The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2006 4.35
7 Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002 3.95
8 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 2004 3.84
9 The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 2003 3.71
10 Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 2004 3.40
11 Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol 2010 3.21
12 Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol 2010 3.02
13 Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol 2011 2.47
14 Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 2005 2.41
15 Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol 2010 2.15
16 Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med 2008 2.05
17 Pharmacogenomics: challenges and opportunities. Ann Intern Med 2006 1.96
18 Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 2012 1.91
19 Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy. J Clin Oncol 2008 1.91
20 A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese. Hum Mol Genet 2011 1.91
21 Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics 2007 1.84
22 Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther 2006 1.84
23 Germline pharmacogenetics of tamoxifen response: have we learned enough? J Clin Oncol 2007 1.76
24 VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics 2008 1.65
25 Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. Am J Psychiatry 2008 1.59
26 Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactions. PLoS Comput Biol 2012 1.58
27 Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst 2012 1.46
28 Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Res Treat 2007 1.41
29 Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples. Pharmacogenetics 2003 1.39
30 Reduced methadone clearance during aromatase inhibition. J Clin Psychopharmacol 2012 1.39
31 High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. Am J Pathol 2003 1.35
32 Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst 2010 1.30
33 Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist 2006 1.30
34 Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum 2004 1.25
35 Creating and evaluating genetic tests predictive of drug response. Nat Rev Drug Discov 2008 1.24
36 Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy. Breast Cancer Res Treat 2008 1.21
37 Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study. Pharmacotherapy 2010 1.21
38 Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. Breast Cancer Res Treat 2009 1.20
39 In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol 2010 1.18
40 Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial. J Chromatogr B Analyt Technol Biomed Life Sci 2003 1.17
41 Possible interethnic differences in quinidine-induced QT prolongation between healthy Caucasian and Korean subjects. Br J Clin Pharmacol 2006 1.16
42 Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. Cancer Res 2010 1.14
43 Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention. Cancer Discov 2013 1.12
44 Predicting asparaginase-associated pancreatitis. Pediatr Blood Cancer 2007 1.10
45 In vitro cytochrome P450-mediated metabolism of exemestane. Drug Metab Dispos 2010 1.10
46 Morbid obesity and metabolic syndrome in Ossabaw miniature swine are associated with increased platelet reactivity. Diabetes Metab Syndr Obes 2011 1.09
47 Human sympathetic activation by alpha2-adrenergic blockade with yohimbine: Bimodal, epistatic influence of cytochrome P450-mediated drug metabolism. Clin Pharmacol Ther 2004 1.09
48 Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants. Nat Rev Cancer 2006 1.08
49 Drug-drug interaction prediction: a Bayesian meta-analysis approach. Stat Med 2007 1.08
50 Association between the CYP3A5 genotype and blood pressure. Hypertension 2004 1.07
51 Analysis of angiogenesis genes from paraffin-embedded breast tumor and lymph nodes. Breast Cancer Res Treat 2006 1.04
52 Differential quantification of CYP2D6 gene copy number by four different quantitative real-time PCR assays. Pharmacogenet Genomics 2010 1.03
53 Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer. Breast Cancer Res Treat 2011 1.02
54 Indexing pharmacogenetic knowledge on the World Wide Web. Pharmacogenetics 2003 1.02
55 In silico and in vitro identification of microRNAs that regulate hepatic nuclear factor 4α expression. Drug Metab Dispos 2012 1.00
56 A modulated empirical Bayes model for identifying topological and temporal estrogen receptor α regulatory networks in breast cancer. BMC Syst Biol 2011 0.99
57 CYP2D6 genotype and tamoxifen response. Breast Cancer Res 2005 0.99
58 Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials. Clin Cancer Res 2011 0.98
59 Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. Clin Pharmacol Ther 2005 0.98
60 The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents. Breast Cancer Res Treat 2011 0.97
61 Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer. Breast Cancer Res Treat 2013 0.96
62 Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance. Clin Cancer Res 2008 0.95
63 Comparison of changes in the lipid profile of postmenopausal women with early stage breast cancer treated with exemestane or letrozole. J Clin Pharmacol 2011 0.95
64 Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism. Drug Metab Dispos 2002 0.94
65 Methadone: a substrate and mechanism-based inhibitor of CYP19 (aromatase). Drug Metab Dispos 2010 0.92
66 Endothelial nitric oxide synthase gene haplotypes associated with circulating concentrations of nitric oxide products in healthy men. Pharmacogenet Genomics 2005 0.91
67 Synthesis of mixed (E,Z)-, (E)-, and (Z)-norendoxifen with dual aromatase inhibitory and estrogen receptor modulatory activities. J Med Chem 2013 0.91
68 Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin. Drug Metab Dispos 2002 0.91
69 Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol 2004 0.91
70 Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4'-methanol-bisbenzonitrile in vitro. Cancer Chemother Pharmacol 2009 0.91
71 Effects of endothelial nitric oxide synthase gene polymorphisms on platelet function, nitric oxide release, and interactions with estradiol. Pharmacogenetics 2002 0.91
72 Identification of genetic variants in the human indoleamine 2,3-dioxygenase (IDO1) gene, which have altered enzyme activity. Pharmacogenet Genomics 2009 0.88
73 C-reactive protein and fibrin clot strength measured by thrombelastography after coronary stenting. Blood Coagul Fibrinolysis 2013 0.87
74 Endothelial nitric oxide synthase haplotypes are related to blood pressure elevation, but not to resistance to antihypertensive drug therapy. J Hypertens 2006 0.87
75 Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing? J Natl Compr Canc Netw 2009 0.87
76 Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer. Breast Cancer Res Treat 2011 0.87
77 CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab Dispos 2004 0.86
78 Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependent on clopidogrel response. Thromb Res 2012 0.86
79 Regulation of microRNA expression by rifampin in human hepatocytes. Drug Metab Dispos 2013 0.85
80 PharmGKB summary: tamoxifen pathway, pharmacokinetics. Pharmacogenet Genomics 2013 0.85
81 Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [13C]pantoprazole breath test. J Pharmacol Exp Ther 2009 0.85
82 Improving the quality of adverse drug reaction reporting by 4th-year medical students. Pharmacoepidemiol Drug Saf 2003 0.85
83 Impact of the Interaction between 3'-UTR SNPs and microRNA on the Expression of Human Xenobiotic Metabolism Enzyme and Transporter Genes. Front Genet 2012 0.84
84 The effects of tamoxifen and its metabolites on platelet function and release of reactive oxygen intermediates. J Pharmacol Exp Ther 2004 0.83
85 The unfinished business of U.S. drug safety regulation. Food Drug Law J 2006 0.83
86 Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response. Clin Pharmacol 2012 0.83
87 Effect of cirrhosis and liver transplantation on the gender difference in QT interval. Am J Cardiol 2005 0.83
88 Effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl metabolites: exploration of a novel CYP2B6 phenotyping index. Br J Clin Pharmacol 2013 0.82
89 Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. Pharmacogenetics 2002 0.82
90 Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes. Br J Pharmacol 2014 0.82
91 Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy. Cancer 2014 0.82
92 Inhibition of cytochrome p450 enzymes by the e- and z-isomers of norendoxifen. Drug Metab Dispos 2013 0.82
93 Enhanced sensitivity to drug-induced QT interval lengthening in patients with heart failure due to left ventricular systolic dysfunction. J Clin Pharmacol 2011 0.81
94 Pharmacotherapy and pregnancy: highlights from the Third International Conference for Individualized Pharmacotherapy in Pregnancy. Clin Transl Sci 2011 0.80
95 Pharmacotherapy and pregnancy: highlights from the Second International Conference for Individualized Pharmacotherapy in Pregnancy. Clin Transl Sci 2009 0.80
96 Functional characterization of a genetic polymorphism in the promoter of the ESR2 gene. Horm Cancer 2012 0.79
97 Discussion: a fresh look at monoamine oxidase inhibitors for depression. J Clin Psychiatry 2012 0.79
98 Creating incentives for genomic research to improve targeting of therapies. Nat Med 2004 0.78
99 A mixture model approach in gene-gene and gene-environmental interactions for binary phenotypes. J Biopharm Stat 2008 0.78
100 Stereoselective pharmacokinetics of stable isotope (+/-)-[13C]-pantoprazole: Implications for a rapid screening phenotype test of CYP2C19 activity. Chirality 2011 0.78
101 Assessment of vascular effects of tamoxifen and its metabolites on the rat perfused hindquarter vascular bed. Basic Clin Pharmacol Toxicol 2009 0.78
102 Cytochrome P450 polymorphisms and their relationship with premature ovarian failure in premenopausal women with breast cancer receiving doxorubicin and cyclophosphamide. Breast J 2011 0.78
103 Sequence diversity and functional characterization of the 5'-regulatory region of human CYP2C19. Pharmacogenetics 2003 0.78
104 Amlodipine--not a significant contributor to clopidogrel non-response? Heart 2013 0.77
105 Pharmacotherapy and pregnancy: Highlights from the first International Conference for Individualized Pharmacotherapy in Pregnancy. Clin Transl Sci 2009 0.77
106 Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin. Platelets 2012 0.77
107 Pharmacokinetics of ibutilide in patients with heart failure due to left ventricular systolic dysfunction. Pharmacotherapy 2008 0.77
108 Exploratory study evaluating the association of polymorphisms of angiogenesis genes with hot flashes. Breast Cancer Res Treat 2008 0.77
109 Pharmacogenetics and healthcare outcomes in patients with chronic heart failure. Eur J Clin Pharmacol 2012 0.77
110 Platelet factor XIIIa release during platelet aggregation and plasma clot strength measured by thrombelastography in patients with coronary artery disease treated with clopidogrel. Platelets 2014 0.76
111 Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype. Drug Metabol Drug Interact 2002 0.76
112 Tamoxifen and its metabolites cause acute vasorelaxation of aortic rings by inducing vasodilator prostanoid synthesis. J Cardiovasc Pharmacol 2011 0.76
113 Whole genome amplification of DNA for genotyping pharmacogenetics candidate genes. Front Pharmacol 2012 0.75
114 PharmGKB summary: ifosfamide pathways, pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics 2014 0.75
115 Is (+)-[13C]-pantoprazole better than (±)-[13C]-pantoprazole for the breath test to evaluate CYP2C19 enzyme activity? J Breath Res 2012 0.75
116 Factor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease. J Thromb Thrombolysis 2014 0.75
117 Methadone adverse reaction presenting with large increase in plasma methadone binding: a case series. J Med Case Rep 2011 0.75
118 In vitro inhibition of pimozide N-dealkylation by selective serotonin reuptake inhibitors and azithromycin. J Clin Psychopharmacol 2002 0.75
119 Induction of testosterone metabolism by esomeprazole in a CYP2C19*2 heterozygote. Am J Med Sci 2004 0.75
120 Editors' report, November 2013. Br J Clin Pharmacol 2014 0.75